History
For more than two decades, Contura has been researching, developing and manufacturing hydrogel
products across multiple therapeutic areas to provide doctors and veterinarians with a proven
long-lasting, non-degradable bio-scaffold injectable.
By working with the scientific and clinical communities in Denmark and across the world, we research and develop
2.5 iPAAG* in areas where we believe a significant clinical need can be met with clinically meaningful results.
Our Milestones
2023
Contura begins expansion of current facility with the aim of fulfilling an expected demand of over 1 million in doses in 2026.
2022
Contura sets up US Animal Health Company, Contura Vet (USA) Inc to commercialise Arthramid Vet in the US.
Contura expands offices in Copenhagen to create work space for over 100 employees.
Results of randomised controlled trial comparing Arthrosamid with hyaluronic acid for treatment of knee osteoarthritis published.
2021
Contura sells Bulkamid to Axonics Modulation Technologies, Inc. and enters into an exclusive manufacturing and supply agreement.
2020
Approval of Bulkamid in the United States by FDA as Class 3 medical device for the treatment of stress urinary incontinence due to intrinsic sphincter deficiency in adult women who have SUI or stress predominant mixed incontinence.
Approval of Arthrosamid in Europe for the treatment of patients with knee osteoarthritis.
Arthramid Vet approved as a drug in Australia.
Arthramid Vet approved as a medical device in USA.
2019
Approval of Arthramid Vet in New Zealand as a novel drug for the treatment of lameness in horses.
Publication in Clinical Orthopedics Advanced Research Journal, of the safety results for Arthrosamid for the treatment of knee osteoarthritis symptoms in a retrospective case series.
2018
Arthramid Vet licensed to Contura Vet for sale in the veterinary market.
2017
Contura’s manufacturing facility is granted EU GMP certificate.
Worldwide rights to Mitem sold with distribution rights for Germany & Austria retained.
2016
Contura completes management buyout as part of plans to strategically focus on 2.5 iPAAG product range.
2015
2 year follow-up of Arthramid Vet clinical study reports with impressive results.
2014
Following impressive results in the clinical study of Arthramid Vet, development of Arthrosamid commences for the treatment of osteoarthritis in the knees of humans.
2013
Worldwide distribution rights for Bulkamid taken back from Ethicon and direct sale by Contura commences.
2007
Contura signs agreement with Johnson & Johnson granting Ethicon, its women’s health subsidiary, exclusive worldwide distribution rights for Bulkamid.
2006
Contura obtains ISO 13485 certificate, having demonstrated its ability to meet customer & regulatory requirements.
2004
Aquamid Reconstruction granted CE-mark for larger volume corrections, rhinoplasty and lipoatrophy.
2003
Bulkamid granted CE-mark for use in the treatment of female urinary incontinence.
2001
Aquamid granted CE-mark for use in facial augmentation.
2000
Contura established.
View more 